Eli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.
But Eli Lilly may be starting to gain an edge over its Danish competitor in the two-horse race to capitalize on the soaring demand for those treatments, also known as GLP-1s.
Feeling out of the loop? We'll catch you up on the Chicago news you need to know. Sign up for the weekly Several analysts were particularly pleased with Eli Lilly's positive manufacturing updates. Demand for weight loss and diabetes drugs is outstripping supply in the U.S., so companies that can quickly get more of a product to patients can gain an edge in the space.
The analysts said there could still be intermittent supply shortages of Mounjaro and Zepbound in the near term"as access improves and physicians get more comfortable with the availability of supply." But they applauded Eli Lilly's progress towards beefing up its manufacturing footprint and supply. Ricks said Eli Lilly's ability to scale up manufacturing of Zepbound and Mounjaro makes the company confident it can compete with newcomers to the weight loss and diabetes drug market that may not have the same capacity."You're talking about making things on the billion scale, which takes time and is technically difficult and very capital-intensive," he continued."So, of course, competitors will have to come.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatmentsQuestions about whether Eli Lilly and Novo Nordisk can maintain their duopoly in weight loss drugs are fair game, but come 'too soon,' one analyst said.
Read more »
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from RocheNovo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche’s latest obesity drug candidate.
Read more »
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from RocheNovo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate.
Read more »
Lilly, Novo Nordisk Battle for Weight-loss Market Lands At the Pharmacy ShelfAs Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is...
Read more »
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager saysYuri Khodjamirian, fund manager at Tema ETFs, says there's a 'valuation opportunity' in biotech stocks at the moment — but also warned of risks.
Read more »
Deutsche Bank says Eli Lilly stock is a buy — in line with our rating on sharesThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »